Dr. Chorny's research program focuses on nanomedicines as well as drug, cell, and gene delivery systems for treating proliferative disease. His current research specifically focuses on the use of nanoparticle-mediated delivery to solid tumors and site-specific delivery for cardiovascular disease.
Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.
Dr. Levy is the director of Cardiology Research, and also serves as program director of the Cardiology National Heart, Lung, and Blood Institute (NHLBI) Research Training Grant. His research interests are the pathophysiology of biomaterials used in medicine, basic mechanisms and novel therapies for heart valve disease, arterial angioplasty, local drug delivery, and nanomedicine. He also has experience over three decades in medical device development.
CHOP has long investigated biodegradable nanoparticles for medical use. With diameters ranging from a few tens to a few hundreds of nanometers, these particles are 10 to 1000 times smaller than red blood cells.
Along with its research partners Drexel University and Hebrew University of Jerusalem, The Children’s Hospital of Philadelphia Research Institute recently hosted a collaborative research symposium that gave researchers from all three institutions the chance to connect and share ideas.
Research in the Brodeur Lab focuses on two main areas: nanoparticle drug delivery and cancer predisposition. Nanomedicines allow the delivery of much more drug to the tumor and much less to the patient.
Research in the Levy Lab centers on the pathophysiology of biomaterials used in medicine, basic mechanisms and novel therapies for heart valve disease, arterial angioplasty, local drug delivery, and nanomedicine.
The laboratory led by Michael Chorny, PhD, designs delivery systems for drugs and biotherapeutics, focusing on vascular proliferative diseases and high-risk malignancies. Biodegradable nanoparticles and prodrugs are optimized to enhance and extend therapeutic activity, and minimize adverse effects.